研究程序性细胞死亡因子4（PDCD4）与原发性肝细胞癌（HCC）患者肝切除术后疾病进展的关系。

选取2022年5月至2024年1月行手术切除的HCC患者130例，采用免疫组织化学方法检测癌组织中PDCD4表达情况，并分析其与HCC患者临床病理特征的关系，采用Kaplan-Meier法进行生存分析，采用单因素及多因素COX回归分析HCC患者肝切除术后疾病进展的影响因素。

HCC组织中PDCD4低表达率为60.0%，高表达率为40.0%。PDCD4低表达与CNLC分期、分化程度及脉管侵犯具有相关性（P<0.05）。PDCD4低表达组术后1年复发率为33.3%，高于PDCD4高表达组的9.6%（P<0.05）。Kaplan-Meier分析显示，PDCD4低表达组术后1年中位无进展生存期（PFS）为6个月，显著短于PDCD4高表达组的9个月（P<0.05）。PDCD4低表达组术后1年PFS率为66.7%，低于PDCD4高表达组的90.4%（P<0.05）。单因素分析显示，肿瘤直径、CNLC分期、分化程度、脉管侵犯、PDCD4表达与HCC患者肝切除术后PFS有关（P<0.05），多因素COX回归分析显示，CNLC分期Ⅲ期（HR=1.923，95%CI: 1.282-2.889）、脉管侵犯（HR=2.331，95%CI: 1.254-4.358）、PDCD4低表达（HR=3.454，95%CI: 1.781-6.688）是HCC患者肝切除术后PFS的独立危险因素（P<0.05）。

PDCD4低表达与HCC患者肝切除术后疾病进展密切相关，是潜在的评估HCC患者肝切除术后疾病进展风险的生物标志物。检测PDCD4的表达水平有望为临床制定治疗方案提供参考依据。

To investigate the relationship between programmed cell death 4 (PDCD4) and disease progression after hepatectomy in patients with primary hepatocellular carcinoma (HCC).

A total of 130 HCC patients who underwent surgical resection from May 2022 to January 2024 were selected. The expression of PDCD4 in cancer tissues was detected by immunohistochemistry, and its relationship with clinicopathological characteristics of HCC patients was analyzed. Survival analysis was performed using the Kaplan-Meier method, and univariate and multivariate COX regression analyses were used to identify influencing factors of disease progression after hepatectomy in HCC patients.

The low expression rate of PDCD4 in HCC tissues was 60.0%, and the high expression rate was 40.0%. Low PDCD4 expression was correlated with CNLC stage, differentiation degree, and vascular invasion (P<0.05). The 1-year postoperative recurrence rate in the low PDCD4 expression group was 33.3%, which was higher than 9.6% in the high PDCD4 expression group (P<0.05). Kaplan-Meier analysis showed that the median 1-year postoperative progression-free survival (PFS) in the low PDCD4 expression group was 6 months, which was significantly shorter than 9 months in the high PDCD4 expression group (P<0.05). The 1-year postoperative PFS rate in the low PDCD4 expression group was 66.7%, which was lower than 90.4% in the high PDCD4 expression group (P<0.05). Univariate analysis showed that tumor diameter, CNLC stage, differentiation degree, vascular invasion, and PDCD4 expression were associated with postoperative PFS in HCC patients (P<0.05). Multivariate COX regression analysis revealed that CNLC stage Ⅲ (HR=1.923, 95%CI: 1.282-2.889), vascular invasion (HR=2.331, 95%CI: 1.254-4.358), and low PDCD4 expression (HR=3.454, 95%CI: 1.781-6.688) were independent risk factors for postoperative PFS in HCC patients (P<0.05).

Low PDCD4 expression is closely related to disease progression after hepatectomy in HCC patients and serves as a potential biomarker for evaluating the risk of disease progression after hepatectomy in HCC patients. Detecting the expression level of PDCD4 is expected to provide a reference for clinical treatment decision-making.